ClinicalTrials.gg
Sign In
WithdrawnNCT05780931AMDUpdated Oct 5, 2026

Rehabilitating Vision Loss in Veterans With Age-Related Macular Degeneration

An observational study in Age-related Macular Degeneration (AMD), sponsored by VA Office of Research and Development. Withdrawn at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by VA Office of Research and Development · Observational

Why this study was withdrawn
I was instructed to stop the study, because the underlying VA grant has run out of funds.
Updated Oct 5, 2026Now WithdrawnStart date moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
0
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-14

Among 645 studies in Macular Degeneration with a site in United States — 84 open to participants now, 128 under way, 24 of them phase 3. Macular Degeneration · United States.

Enrollment
144th of 146
0 · median 100
Started
2024
with 23 others
Observational
146 of 645
25 open now
Registered
539th of 645
by date

Among the 645 studies in Macular Degeneration with a site in United States, this one is the 144th largest by enrollment of the 146 observational ones that give a count, is one of 24 that started in 2024, is one of 146 observational ones, and was the 539th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

84 of the 645 studies in Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:

79 more — sign in →

All 84 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Macular Degeneration with a site in United States, or all of them as a file.
02

Study summary

This study will help develop new methods of rehabilitating Veterans with vision loss due to Age-related macular degeneration.

Read the detailed description

The purpose of this research study is to develop new and improved methods of helping vision-impaired Veterans see better by using hands as "seeing eyes". This study will focus on Veterans with a common form of eye disease called age-related macular degeneration that affects older individuals.

03

Conditions studied

  • Age-related Macular Degeneration (AMD)

Keywords

  • Maculopathy
  • Macular dystrophy
  • Drusen
  • wet AMD
  • dry AMD
04

Who can participate

The criteria were revised on the registry on Sep 29, 2026. See what changed

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Veterans with vision loss caused by age-related macular degeneration

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject is a Veteran
  • The subject has best-corrected visual acuity (BCVA) of 20/40 or worse in each eye, as determined by the standard Charlie Norwood VA Medical Center (CNVAMC) optometric tests
  • The subject has visual field deficit of 10O in either eye as determined by the Octopus 900 perimetry (Haag-Streit Diagnostics, Haag-Streit USA, Mason, OH) administered by CNVAMC. (When the deficit/s are binocular, they do not necessarily have to be in binocularly corresponding positions)
  • The subject has received a formal clinical diagnosis of age-related macular degeneration (AMD) in one or both eyes (binocular AMD does not necessarily have to be in binocularly corresponding positions)
  • The subject has visual deficit in either eye (wavy lines and/or missing/darkened areas on the grid) determined by the standard Amsler Grid Test
  • The subject has not yet started any rehabilitative treatment for AMD-related vision loss
  • Both eyes of the subject are otherwise age-appropriately stable, and neither eye has any other visual defects, as determined by the standard CNVAMC ophthalmological examination
  • The subject must be able to understand the nature and individual consequences of the study
  • The subject must be able to provide signed and dated before start of any participation in the study procedures (11)Women with must test negative for pregnancy using a standard urine test prior to participating in each functional magnetic resonance imaging (fMRI) procedure. (This exclusion criterion is mandated by the Augusta University Institutional Review Board [AU IRB], which also serves as the IRB of record of the CNVAMC. It is intended as an extra precautionary measure to help ensure the health and safety of this vulnerable population. The proposed study will comply with this requirement.)

Exclusion criteria

Exclusion Criteria:

  • According to the patient's VA clinical records, the patient has one or more clinically diagnosed neurological disorder
  • According to the patient's VA clinical records, the patient has one or more clinically diagnosed cognitive deficits
  • According to the patient's VA clinical records, the patient has been clinically diagnosed with a psychiatric disorder that would make it unduly uncomfortable or otherwise clinically inadvisable for the subject to participate in the study
  • According to the patient's VA clinical records, according to the patient, or both, the patient has motor disorder/s that would make it unduly uncomfortable or otherwise clinically inadvisable for the subject to participate in the study
  • According to the patient's VA clinical records, according to the patient, or both, the patient has an MR-incompatible implant and/or another condition (e.g., claustrophobia) that would make it inadvisable for the subject to participate in MR imaging or any other study procedure
  • The patient does not understand the information and/or the standard study instructions in spoken or written English, and/or is unable to follow study instructions. [The purpose of this exclusion criterion, required by the AU IRB, is to help ensure that the subjects adequately understand all the information relevant to providing informed consent, as well as the study instructions.]
  • Inability to give informed consent to participate in the study
  • Pregnancy, as determined by a standard urine test for pregnancy
  • Participation in other study/studies including an drug or device during the present study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
0 participants (actual)
Patient registry
No

Groups and cohorts

  • Treatment Group

    This is the group of study subjects which will undergo study-related rehabilitation procedures.

    Behavioral: Study-specific rehabilitation (SSR) procedures

  • Control Group

    This is the group of study subjects which will undergo control (sham) rehabilitation procedures (in addition to all their regularly scheduled treatments and interventions).

Interventions

  • BehavioralStudy-specific rehabilitation (SSR) procedures

    Study-specific rehabilitation procedures will systematically manipulated the spatial or temporal synchrony (or coordination) of visual vs. haptic inputs that the subjects receive.

    Also known as: Study-related rehabilitation procedures

06

What researchers measure

Primary outcomes

  1. Accuracy of object recognition

    This outcome will be measured as the accuracy (% correct) with which the study subjects recognize the text objects before, during and after their participation in the study procedures.

    Time frame: 6-10 weeks

  2. Response of brain regions of interest (ROI) as reflected in the BOLD (blood oxygenation level-dependent) response

    This outcome will be measured as changes (if any) of the BOLD responses of brain ROIs before, during and after their participation in the study procedures.

    Time frame: 6-10 weeks

07

Study locations

1 site
  • Charlie Norwood VA Medical Center, Augusta, GA
    Augusta, Georgia 30904-6258, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jan 2024 to primary completion in Sep 2026, 32 months.

Start moved twice since we started tracking on Sep 25, 2026: Aug 2026 → Jan 2024, last on Oct 5, 2026.

Primary completion moved once since we started tracking on Sep 25, 2026: May 2027 → Sep 2026, on Oct 5, 2026.

Completion moved once since we started tracking on Sep 25, 2026: May 2027 → Sep 2026, on Oct 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2023
First posted
Mar 23, 2023
StartActual
Jan 1, 2024was Aug 2026
Primary completionActual
Sep 29, 2026was May 2027
CompletionActual
Sep 29, 2026was May 2027
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Withdrawn I was instructed to stop the study, because the underlying VA grant has run out of funds.
changed Oct 5, 2026
Start date
Aug 3, 2026→Jan 1, 2024 (actual)
moved 2 times, Sep 29, 2026 – Oct 5, 2026
Primary completion
May 31, 2027→Sep 29, 2026 (actual)
Oct 5, 2026
Study completion
May 31, 2027→Sep 29, 2026 (actual)
Oct 5, 2026
Enrollment
20 (estimated)→0 (actual)
Oct 5, 2026
Eligibility
5 inclusion criteria edited, 2 removed
What changed in the criteria
Inclusion criteria
  • RemovedThe subject is 50 years of age.
  • EditedThe subject has best-corrected visual acuity (BCVA) of 20/40 or worse in each eye, as determined by the standard Charlie Norwood VA Medical Center (CNVAMC) optometric tests.
  • EditedThe subject has visual field deficit of 10O in either eye as determined by the Octopus 900 perimetry (Haag-Streit Diagnostics, Haag-Streit USA, Mason, OH) administered by CNVAMC. (When the deficit/s are binocular, they do not necessarily have to be in binocularly corresponding positions.)
  • EditedThe subject has received a formal clinical diagnosis of age-related macular degeneration (AMD) in one or both eyes (binocular AMD does not necessarily have to be in binocularly corresponding positions)7,8,56.
  • EditedThe subject has visual deficit in either eye (wavy lines and/or missing/darkened areas on the grid) determined by the standard Amsler Grid Test7,8,56.Test
  • RemovedThe subject must be able to provide signed and dated informed consent before start of any participation in the study procedures.
  • EditedThe subject must be able to provide signed and dated informed consent before start of any participation in the study procedures (11)Women with childbearing potential must test negative for pregnancy using a standard urine test prior to participating in each functional magnetic resonance imaging (fMRI) procedure. (This exclusion criterion is mandated by the Augusta University Institutional Review Board [AU IRB], which also serves as the IRB of record of the CNVAMC. It is intended as an extra precautionary measure to help ensure the health and safety of this vulnerable population. The proposed study will comply with this requirement.)
Sep 29, 2026
Show all 2 updates
  1. Oct 5, 2026
    Not yet recruiting→Withdrawn
    Why stopped I was instructed to stop the study, because the underlying VA grant has run out of funds.
    Start date Oct 1, 2026→Jan 1, 2024 (now actual)
    Primary completion May 31, 2027→Sep 29, 2026 (now actual)
    Study completion May 31, 2027→Sep 29, 2026 (now actual)
    Enrollment 20 (estimated)→0 (actual)
    + 1 other change: contact details
  2. Sep 29, 2026
    Start date Aug 3, 2026→Oct 1, 2026
    Eligibility 5 inclusion criteria edited, 2 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedThe subject is 50 years of age.
    • EditedThe subject has best-corrected visual acuity (BCVA) of 20/40 or worse in each eye, as determined by the standard Charlie Norwood VA Medical Center (CNVAMC) optometric tests.
    • EditedThe subject has visual field deficit of 10O in either eye as determined by the Octopus 900 perimetry (Haag-Streit Diagnostics, Haag-Streit USA, Mason, OH) administered by CNVAMC. (When the deficit/s are binocular, they do not necessarily have to be in binocularly corresponding positions.)
    • EditedThe subject has received a formal clinical diagnosis of age-related macular degeneration (AMD) in one or both eyes (binocular AMD does not necessarily have to be in binocularly corresponding positions)7,8,56.
    • EditedThe subject has visual deficit in either eye (wavy lines and/or missing/darkened areas on the grid) determined by the standard Amsler Grid Test7,8,56.Test
    • RemovedThe subject must be able to provide signed and dated informed consent before start of any participation in the study procedures.
    • EditedThe subject must be able to provide signed and dated informed consent before start of any participation in the study procedures (11)Women with childbearing potential must test negative for pregnancy using a standard urine test prior to participating in each functional magnetic resonance imaging (fMRI) procedure. (This exclusion criterion is mandated by the Augusta University Institutional Review Board [AU IRB], which also serves as the IRB of record of the CNVAMC. It is intended as an extra precautionary measure to help ensure the health and safety of this vulnerable population. The proposed study will comply with this requirement.)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05780931
Lead sponsor
VA Office of Research and Development
Collaborators
Augusta University
Responsible party
Sponsor
First posted
Mar 23, 2023
Start date
Jan 1, 2024
Primary completion
Sep 29, 2026
Completion
Sep 29, 2026
Last update
Oct 5, 2026

Study contacts

Jay Hegde, PhD
principal investigator · Charlie Norwood VA Medical Center, Augusta, GA

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Macular Degeneration →

Other studies from this sponsor

VA Office of Research and Development →

Start the discussion